A Pilot Study in Normal Volunteers of the Effects of the Renuva™ System on Growth Hormone and Insulin-Dependent Growth Factor-1

Abstract

Background: The Renuva™ System is a dietary supplement sold to prevent symptoms of age-related growth hormone decline. Objective: Test the ability of the Renuva™ System to increase growth hormone (GH) and insulin-like growth factor-1 (IGF-1). Methods: The Renuva™ System is a two-part dietary supplement to maintain a healthy endocrine system. The contains amino acids and nicotinic acid. The contains growth hormone releasing peptides in a pat- ented oral delivery system. The Renuva™ System was given to 13 healthy volunteers >40 years. Two of 13 subjects were given just the to swallow, and four subjects were given just the on a second occasion. GH and IGF-1 were measured at -10, -5, 0, 30, 60, 90, 120, and 180 minutes. Results: Thirteen subjects receiving the two-part Renuva™ System increased GH 98 + 50.2% (SEM) (p<0.05) from base- line, and IGF-1 rose 35.8 + 45.0 ng/mL (p<0.02) from baseline at 120 minutes. Average IGF-1 levels of 2 subjects receiv- ing just the was less 174.8 + 20.8 ng/ml) than average IGF-1 post-baseline values during the test using both the Infuser Spray and Generator drink (213 + 37.2 ng/mL, p<0.002). Average IGF-1 levels of 4 subjects receiving just the was less (202.6 + 124.7 ng/mL) than average IGF-1 post-baseline values when using both the Infuser spray and the Generator drink (234.8 + 32.2 ng/mL, p=NS). Conclusion: The Renuva™ System increases GH and IGF-1. Both the Generator Drink and the Infuser Spray appear to contribute to the increase in IGF-1.